Streetbeat News

Stock Prices

RAPT

RAPT Therapeutics shares are trading higher as the stock rebounds from a previous sell-off. The sell-off occurred after the company announced that the FDA placed a clinical hold on its Phase 2b trial of zelnecirnon, leading to increased volatility.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:11 pm

DD

DuPont is scheduled to present at the Barclays Industrial Select Conference, leading to a spike in its shares. The presentation will be from 10:55 a.m. to 11:25 a.m. ET, with a live audio webcast accessible through the DuPont Investor Relations webpage. A replay of the webcast will be available after the presentation.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:09 pm

CLH

Clean Harbors reported lower-than-expected Q4 revenue results, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:05 pm

JNJ

The FDA has approved Johnson & Johnson's (NYSE:JNJ) application for a reduced dosing frequency of Tecvayli in patients with relapsed or refractory multiple myeloma (RRMM) who have maintained a complete response for at least six months. This approval, based on the Phase 1/2 MajesTEC-1 study, allows for a dosing frequency of 1.5 mg/kg every two weeks. Tecvayli, a bispecific antibody targeting BCMA and CD3, was initially approved in October 2022 for RRMM patients after at least four prior lines of therapy. Over 3,600 patients in the U.S. have been prescribed Tecvayli since its approval.

Portfolio Pulse from Vandana Singh

February 21, 2024 | 4:04 pm

RAPT

RAPT Therapeutics shares have declined following downgrades from multiple firms.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:04 pm

UVE

Universal Insurance Holdings (NYSE:UVE) is scheduled to release its quarterly earnings report on February 22, 2024. Analysts predict an EPS of $0.25. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting variably. Shares are currently trading at $17.41, up 38.08% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:02 pm

VICR

Vicor (NASDAQ:VICR) is scheduled to release its quarterly earnings report on February 22, 2024, with analysts expecting an EPS of $0.32. The company's past earnings performance shows a mixed impact on its stock price, with significant fluctuations following earnings announcements. Vicor's stock has been trading at $47.18 as of February 20, reflecting a 16.92% decline over the last 52 weeks. Investors are looking for positive guidance for the next quarter beyond the earnings beat.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:02 pm

ZEUS

Olympic Steel (NASDAQ:ZEUS) is scheduled to release its quarterly earnings report on February 22, 2024. Analysts predict an EPS of $0.30. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting accordingly. Shares are currently trading at $69.47, up 50.51% over the last 52 weeks. Investors are looking for not just an earnings beat but also positive guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:02 pm

ZIP

ZipRecruiter (NYSE:ZIP) is expected to report an EPS of $0.07 in its upcoming quarterly earnings on February 22, 2024. Analysts and investors are looking for an earnings beat and positive guidance for the next quarter. Historical data shows mixed reactions to past earnings, with the last quarter's beat resulting in a slight stock price increase. Over the last year, ZIP shares have declined by 20.36%, indicating potential concern among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

AIV

Apartment Inv & Mgmt (NYSE:AIV) is scheduled to release its quarterly earnings report on February 22, 2024, with an expected EPS of $-0.06. Historical data shows the company has previously beaten EPS estimates, leading to positive stock price movements. Shares are currently trading at $7.67, reflecting a 2.78% increase over the last 52 weeks. Investors are optimistic but will focus on the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm